The Pharmaceutical Industry’s 10 Biggest R&D Budgets
Innovation is everything when it comes to the pharmaceutical sector.
Posts Tagged ‘OTCBB:RHHBY’
Everything You Need to Know About the Upcoming Flu Season
To me, flu season is a lot like Christmas; there's a defined time period when we expect it to occur, yet it seems to appear earlier and earlier every year.
Sanofi SA (ADR) (SNY), Roche Holding Ltd. (ADR) (RHHBY), GlaxoSmithKline plc (ADR) (GSK): Is the Tide About to Turn in the Fight Against Chronic Lymphocytic Leukemia?
There is perhaps nothing scarier than a cancer diagnosis.
Regeneron Pharmaceuticals Inc (REGN): Should You Follow in Sanofi SA (ADR) (SNY)’s Footsteps and Invest in This Booming Biotech?
More than anything, biotech companies need investors who are true believers in their products.
Bristol Myers Squibb Co. (BMY), Merck & Co., Inc. (MRK): Is AstraZeneca plc (ADR) (AZN)’s Recent Acquisition Bigger Than Onyx?
AstraZeneca plc (ADR) (NYSE:AZN) may have missed out on acquiring the oncology platform of Onyx Pharmaceuticals, but it responded by pulling the trigger on a $500 million deal...
What Does Roche Holding Ltd. (ADR) (RHHBY)’s Inovio Pharmaceuticals Inc (INO) Deal Mean for Investors?
Especially in the health care sector, a company's technology can matter much more than most other aspects of its business.
Theravance Inc (THRX), GlaxoSmithKline plc (ADR) (GSK): Investors Should Brace for a Busy Week From the Biotech Sector
With second-quarter earnings season now in the books and about a month to go before third-quarter earnings kicks off, biotech savvy investors are in for a treat this week with...
Sarepta Therapeutics Inc (SRPT), GlaxoSmithKline plc (ADR) (GSK): An Edge Emerges in the Race to Treat Muscular Dystrophy
In a previous article, I speculated on the race to develop a Duchenne muscular dystrophy, or DMD, drug and who might win it.
Roche Holding Ltd. (ADR) (RHHBY), Eli Lilly & Co. (LLY): Understanding the Massive Market Potential of Monoclonal Antibodies
Over the past several years, monoclonal antibodies have revolutionized cancer treatments.
Curis, Inc. (CRIS), Bristol Myers Squibb Co. (BMY), Novartis AG (ADR) (NVS): Can Stopping This Hedgehog Create New Cancer Treatments?
Curis, Inc. (NASDAQ:CRIS) and Roche Holding Ltd.
Galena Biopharma Inc (GALE), Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Could This Breast Cancer Vaccine Be a Game Changer?
Breast cancer claims more than 40,000 lives in the United States annually and is one of the leading causes of death for females globally.
Onyx Pharmaceuticals, Inc. (ONXX), Amgen, Inc. (AMGN), Alexion Pharmaceuticals, Inc. (ALXN): Biotech’s Falling Fortunes Stymie Osiris Therapeutics, Inc. (OSIR)’s Huge Week
Biotech's the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling up or down by significant amounts...
Medidata Solutions Inc (MDSO), salesforce.com, inc. (CRM): I’m Buying This High-Flying Stock Now
Every month, I select one or more stocks that I'll be buying in real life for my Roth IRA.
GlaxoSmithKline plc (ADR) (GSK), Roche Holding Ltd. (ADR) (RHHBY): Why Alex Rodriguez Could Bring Big Business to This Sector
Baseball star Alex Rodriguez had an opportunity to be perhaps the greatest player of the past decade or even longer -- that was until he threw it all away by admitting to steroid...
Alnylam Pharmaceuticals, Inc. (ALNY)’s Surge Caps Off a Strong Week in Biotech
Biotech's the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling up or down by significant amounts...
Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): One Weight-Loss Drug That Investors Forgot
You know Belviq and Qsymia and Contrave and Empatic, but do you recall the still most widely used weight-loss drug of all? It seems almost like ancient history now, but back in...
Viropharma Inc (VPHM), Actavis Inc (ACT), Akorn, Inc. (AKRX): Can This Experimental Drug Be Brought Back From the Dead?
Five years ago, Viropharma Inc (NASDAQ:VPHM) had everything going for it.
Bristol Myers Squibb Co. (BMY): This Pharma Is Trading Like a Biotech
This chart is just unbelievable.
Bristol Myers Squibb Co. (BMY), Ariad Pharmaceuticals, Inc. (ARIA): ASCO Investment Ideas
The American Society of Clinical Oncology annual meeting kicks off today.
Dendreon Corporation (DNDN): This Cancer Drug Developer Could Really Use a Partner
As we've learned over the past few years, getting a drug approved by the Food and Drug Administration is just half the battle in the biotech sector.
Dendreon Corporation (DNDN), Bristol Myers Squibb Co. (BMY): Why Immunotherapy Stocks Could Be Set for a Big Move
If the JPMorgan Healthcare Conference in January is the mecca of all health-care events during the year, then the American Society of Clinical Oncology's annual meeting in Chicago...
Pfizer Inc. (PFE), Sanofi SA (ADR) (SNY), Onyx Pharmaceuticals, Inc. (ONXX): Will ASCO Unlock Big Value in This Cancer Drug Class?
Avastin -- which the Food and Drug Administration has approved to treat metastatic colorectal cancer (as a first-line and second-line treatment), metastatic HER2-negative breast...
Roche Holding Ltd. (ADR) (RHHBY), Bristol Myers Squibb Co. (BMY): Cancer Meeting Highlights the Good and Bad of the Immune System
Biotech investors rejoice. The ASCO abstracts are here.
AstraZeneca plc (ADR) (AZN): Where Investment Dollars Are Headed
As I noted 10 weeks ago, cancer statistics are both staggering and disappointing.
Allergan, Inc. (AGN), Regeneron Pharmaceuticals Inc (REGN), And What You Should Know
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Sarepta Therapeutics Inc (SRPT): FDA Says, “Call Me Maybe”
A lot has been written this week -- at The Fool and elsewhere -- about Sarepta Therapeutics Inc (NASDAQ:SRPT)' update on its meeting with the Food and Drug Administration.
Thermo Fisher Scientific Inc. (TMO): Is It Getting a Good Deal With Life Technologies Corp. (LIFE)?
Thermo Fisher Scientific Inc. (NYSE:TMO) announced today that it will acquire genomics company Life Technologies Corp. (NASDAQ:LIFE) in a $13.6 billion deal.
Sanofi SA (ADR) (SNY), Aegerion Pharmaceuticals, Inc. (AEGR): ISIS Pharmaceuticals, Inc. (ISIS), Big Pharma’s Little Friend
Roche Holding Ltd. (ADR) (PINK:RHHBY) and ISIS Pharmaceuticals, Inc.
International Business Machines Corp. (IBM): This Company & Genentech Introduce a New Era
International Business Machines Corp. (NYSE:IBM) knew it had something big on its hands when it introduced the System/360 series of mainframe computers on April 7, 1964.
Bristol Myers Squibb Co. (BMY), Amgen, Inc. (AMGN): Tackling Cancer: Melanoma’s Biggest Current & Upcoming Players
As I noted five weeks ago, cancer statistics are both staggering and disappointing.
AstraZeneca plc (ADR) (AZN), Sanofi SA (ADR) (SNY), GlaxoSmithKline plc (ADR) (GSK): Is It Worth Getting a Flu Shot? The Answer May Surprise You…
Every year, it appears that flu season starts earlier and earlier, and somehow, every year, the virus mutates into its "most virulent form ever." Sometimes it's a wonder we even...
Pfizer Inc. (PFE), Celgene Corporation (CELG): Tackling Cancer: Lung Cancer’s Biggest Current and Upcoming Players
As I noted three weeks ago, cancer statistics are both staggering and disappointing.
Tackling Cancer: Breast Cancer’s Biggest Current & Upcoming Players – Roche Holding Ltd. (ADR) (RHHBY), AstraZeneca plc (ADR) (AZN), ImmunoGen, Inc. (IMGN)
As I noted two weeks ago, cancer statistics are both staggering and disappointing.
CAPScall of the Week: Clovis Oncology Inc (CLVS)
For years, satirical late-night TV host Stephen Colbert has been running a series on his show called "Better Know a District," which highlights one of the 435 U.S.
This FDA Approval Is Actually a Big Deal: Dendreon Corporation (DNDN)
As we've learned in recent years, getting an approval from the Food and Drug Administration is only half the battle.
Amgen, Inc. (AMGN)’s Future Is Brighter Than You Might Think
When you think about a cutting-edge, one-foot-in-the-future biotech company, no one would blame you for skipping over Amgen, Inc. (NASDAQ:AMGN).
